These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27374322)

  • 1. Does cannabidiol have a role in the treatment of schizophrenia?
    Gururajan A; Malone DT
    Schizophr Res; 2016 Oct; 176(2-3):281-290. PubMed ID: 27374322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the antipsychotic properties of cannabidiol in humans.
    Iseger TA; Bossong MG
    Schizophr Res; 2015 Mar; 162(1-3):153-61. PubMed ID: 25667194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Could cannabidiol be used as an alternative to antipsychotics?
    Fakhoury M
    J Psychiatr Res; 2016 Sep; 80():14-21. PubMed ID: 27267317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabidiol as a potential treatment for psychosis.
    Schubart CD; Sommer IE; Fusar-Poli P; de Witte L; Kahn RS; Boks MP
    Eur Neuropsychopharmacol; 2014 Jan; 24(1):51-64. PubMed ID: 24309088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
    Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS
    Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabidiol monotherapy for treatment-resistant schizophrenia.
    Zuardi AW; Hallak JE; Dursun SM; Morais SL; Sanches RF; Musty RE; Crippa JA
    J Psychopharmacol; 2006 Sep; 20(5):683-6. PubMed ID: 16401651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects.
    Breuer A; Haj CG; Fogaça MV; Gomes FV; Silva NR; Pedrazzi JF; Del Bel EA; Hallak JC; Crippa JA; Zuardi AW; Mechoulam R; Guimarães FS
    PLoS One; 2016; 11(7):e0158779. PubMed ID: 27416026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
    Roser P; Vollenweider FX; Kawohl W
    World J Biol Psychiatry; 2010 Mar; 11(2 Pt 2):208-19. PubMed ID: 20218784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabidiol and Sodium Nitroprusside: Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis.
    Crippa JA; Hallak JE; Abílio VC; de Lacerda AL; Zuardi AW
    CNS Neurol Disord Drug Targets; 2015; 14(8):970-8. PubMed ID: 26350340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
    Mandolini GM; Lazzaretti M; Pigoni A; Oldani L; Delvecchio G; Brambilla P
    Epidemiol Psychiatr Sci; 2018 Aug; 27(4):327-335. PubMed ID: 29789034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
    Deiana S
    Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation.
    Zuardi AW; Crippa JA; Hallak JE; Bhattacharyya S; Atakan Z; Martin-Santos R; McGuire PK; Guimarães FS
    Curr Pharm Des; 2012; 18(32):5131-40. PubMed ID: 22716160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.
    Gururajan A; Taylor DA; Malone DT
    Behav Brain Res; 2011 Sep; 222(2):299-308. PubMed ID: 21458498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia.
    Thériault RK; St-Denis M; Hewitt T; Khokhar JY; Lalonde J; Perreault ML
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of cannabidiol oil in schizophrenia treatment. a systematic review and meta-analysis.
    Kopelli E; Samara M; Siargkas A; Goulas A; Papazisis G; Chourdakis M
    Psychiatry Res; 2020 Sep; 291():113246. PubMed ID: 32599446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials.
    Silvestro S; Mammana S; Cavalli E; Bramanti P; Mazzon E
    Molecules; 2019 Apr; 24(8):. PubMed ID: 31013866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
    Levin R; Almeida V; Peres FF; Calzavara MB; da Silva ND; Suiama MA; Niigaki ST; Zuardi AW; Hallak JE; Crippa JA; Abílio VC
    Curr Pharm Des; 2012; 18(32):4960-5. PubMed ID: 22716146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is cannabidiol an effective treatment for schizophrenia?
    Guinguis R; Ruiz MI; Rada G
    Medwave; 2017 Aug; 17(7):e7010. PubMed ID: 28820868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
    Crippa JA; Guimarães FS; Campos AC; Zuardi AW
    Front Immunol; 2018; 9():2009. PubMed ID: 30298064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.